Guidelines of clinical practice of the serv: Management of ocular complications of diabetes. diabetic retinopathy and macular oedema;Guías de práctica clínica de la serv: manejo de las complicaciones oculares de la diabetes. retinopatía diabética y edema macular

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 84, Issue 9, 2009, Pages 429-450

  Ríos, Alicia Pareja ^a   Serrano Garcia M A ^a   Marrero Saavedra, M D ^b   Abraldes Lopez V M ^c   Reyes Rodriguez M A ^b   Cabrera Lopez F ^d   Lopez Galvez M ^e   Cardona Guerra, P ^d   Abreu Reyes, P ^f   Quijada Fumero, E ^a   Coronado Toural, A ^g   Gutierrez Sanchez E ^h   Gil Hernandez M A ^f   Valls Quintana, P ^b   Marin Olmos F ⁱ   Navarro Alemany, R ^j  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^f HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^g Clínica Cirugía Ocular de Madrid S L   (Spain)

^h Orbit Unit Clínica Piñero   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j Ocular Microsurgery Institute   (Spain)

more..

Author keywords

Diabetic macular oedema; Diabetic retinopathy; Intravitreal antiangiogenic drugs; Optic coherence tomography; Photocoagulation; Vitrectomy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

ARTICLE; CATARACT; CATARACT EXTRACTION; CLASSIFICATION; DIABETES MELLITUS; DIABETIC RETINOPATHY; ECHOGRAPHY; FLUORESCENCE ANGIOGRAPHY; HOSPITALIZATION; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; LASER COAGULATION; METHODOLOGY; OPTICAL COHERENCE TOMOGRAPHY; PRACTICE GUIDELINE; RETINA HEMORRHAGE; RETINA MACULA EDEMA; VITRECTOMY; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CATARACT; CATARACT EXTRACTION; DIABETES COMPLICATIONS; DIABETIC RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS, INTRAOCULAR; LIGHT COAGULATION; MACULAR EDEMA; RETINAL HEMORRHAGE; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, OPTICAL COHERENCE; VITRECTOMY; VITREOUS BODY;

EID: 75649112652     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Bloomgarden TZ. Diabetic retinopathy. Diabetes Care 2008; 31: 1080-1083.
2. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report number 10. Early treatment diabetic retinopathy study research group. Ophthalmology 1991; 98: 786-806.
3. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-1682.
4. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effects to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early treatment diabetic retinopathy study research group. Arch Ophthalmol 1995; 113: 1144- 1155.
5. Sander B, Larsen M, Engler C, Strom C, Moldow B, Larsen N, et al. Diabetic macular oedema: a comparison of vitreous fluorometry, angiography, and retinopathy. Br J Ophthalmol 2002; 86: 316-320.
6. Zein WM, Noureddin BN, Jurdi FA, Schakal A, Bashshur ZF. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management proliferative diabetic retinopathy with macular edema. Retina 2006; 26: 137-142.
7. Kumar A, Sinha S, Azad R, Sharma YR, Vohra R. Comparative evaluation of vitrctomy and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2007; 245: 360-368.
8. Lee CM, Olk RJ. Modifies grid laser photocoagulation for diffusse diabetic macular edema. Long term visual results. Ophthalmology 1991; 98: 1594-1602.
9. Lee CM, Olk RJ, Akduman L. Combined modified grid and panretinal photocoagulation for diffusse diabetic macular edema and proliferative diabetic retinopathy. Ophthalmic Surg Lasers 2000; 31: 292-300.
10. Akduman L, Olk RJ. Subthreshold (invisible) modified grid and diodo laser photocoagulation in diffusse diabetic macular edema (DDME). Ophthalmic Surg Lasers 1999; 30: 706-714.
11. Akduman L, Olk RJ. Laser photocoagulation of diabetic macular edema. Ophthalmic Surg Lasers 1997; 28: 387- 408.
12. Panozzo G, Parolini B, Gusson E, Mercanti A, Pinackatt S, Bertoldo G, et al. Diabetic macular edema: an OCT-based classification. Semin Ophthalmol 2004; 19: 13-20.
13. American Diabetes Association. Diabetes Care. 2008; 31: S1-S2.
14. Olafsdóttir E, Stefánsson E. Biennial eye screening in patients with diabetes without retinopathy: 10-year experience. Br J Ophthalmol 2007; 91: 1599-1601.
15. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995; 102: 647-661.
16. Retinopathy and nephropathy in patients with type 1 diabetes four year after a trial of intensive therapy. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N England J Med 2003; 42: 381-389.
17. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983.
18. The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin- dependent diabetes mellitus. Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
19. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
20. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study (UKPDS) Group. BMJ 1998; 317: 703-713.
21. Verdaguer Tarradella J. Clasificación de la Retinopatía diabética. En: Alfaro V, Gómez-Ulla F, Quiroz-Mercado H, Figueroa MS. Villalba SJ. Retinopatía diabética. Tratado médico quirúrgico. Madrid: Mac Line, S.L. 2006; 43-50.
22. Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003; 110: 2386-2394.
23. Sothornwit N. Intravitreal bevacizumab for ahmed glaucoma valve implantation in neovascular glaucoma: a case report. J Med Assoc Thai 2008; 91: S162-S165.
24. Mason JO 3rd, Yunker JJ, Vail R, McGwin G Jr. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation- induced complications in patients with severe proliferative diabetic retinopathy. Retina 2008; 28: 1319-1324.
25. National Eye Institute (NEI). Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy (LRTforDME+ PRP). Clinical Trials gov Identifier: NCT00445003, July 2008.
26. Álvarez López A, Canut Jorda, MI. Estudio de bevacizumab (Avastin) intravítreo en el tratamiento del glaucoma neovascular. Anales Instituto Barraquer 2008, 37: 75-85.
27. Ruiz-Moreno JM, Montero JA, Lugo F, Amat P, Staicu C. Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy. Acta Ophthalmol 2008; 86: 231-232.
28. Jonas JB, Libondi T, von Baltz S, Vossmerbaeumer U. Intravitreal bevacizumab for vitreous haemorrhage. Acta Ophthalmol 2008; 86: 585-586.
29. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275-278.
30. Arévalo F, Alfaro V, García RA, Fernández CF. Complicaciones de la vitrectomía en el paciente diabético. En: Alfaro V, Gómez-Ulla F, Quiroz-Mercado H, Figueroa MS. Villalba SJ. Retinopatía diabética. Tratado médico quirúrgico. Madrid: MacLine, S.L. 2006; 445-462.
31. Ruiz-Moreno JM, Montero JA, Lugo F, Amat P, Staicu C. Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy. Acta Ophthalmol 2008; 86: 231-232.
32. Berrocal MH. Proliferación Fibrovascular Hialoidea Anterior. En: Alfaro V, Gómez-Ulla F, Quiroz-Mercado H, Figueroa MS. Villalba SJ. Retinopatía diabética. Tratado médico quirúrgico. Madrid: MacLine, S.L. 2006; 425-429.
33. Engelbert M, Del Priore L, Al-Aswad A. Neovascular Glaucoma. Contemporary Ophthalmology 2008; 7: 15.
34. Hong C, Arosemena A, Zurakowowski D, Ayyala RS. Glaucoma drainage devices: a sistematic literature review and current controversies. Diagnostic and surgical techniques. Surv Ophthalmol 2005; 50: 48-60.
35. Ichhpujani P, Ramasubramanian A, Kaushik S, Pandav S. Bevacizumab in glaucoma: a review. Can Ophthalmol 2007; 42: 812-815.
36. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008; 18: 263-269.
37. Schlote T, Derse M, Rassmann K, Nicaeus T, Dietz K, Thiel HJ. Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma. J Glaucoma 2001; 10: 294-301.
38. Miki A, Oshima Y, Otori Y, Kamei M, Tano Y. Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma. Br J Ophthalmol 2008; 92: 1431-1433.
39. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther 2008; 25: 438-443.
40. European Glaucoma Society Terminology and guidelines for glaucoma. Italy: Dogma. 2008.
41. Jurecka T, Bátková Z, Ventruba J, Synek S. Macular edema after cataract surgery in diabetic patients without retinopathy. Cesk Slov Oftalmol 2007; 63: 274-284.
42. Macugen to prevent worsening of macular edema following cataract surgery in diabetics. Information provided by: Johns Hopkins University. Clinical Trials Gov Identifier: NCT00346983.
43. Triamcinolona. Clinical Trial Gov Identifier: NCT00801450.
44. Estabrook EJ, Madhusudhana KC, Hannan SR, Newsom RS. Can optical coherence tomography predict the outcome of laser photocoagulation for diabetic macular edema? Ophthalmic Surg Lasers Imaging 2007; 38: 478-483.
45. Kaderli B, Avci R, Gelisken O, Yucel AA. Intravitreal triamcinolone as an adjunct in the treatment of concomitant proliferative diabetic retinopathy and diffuse diabetic macular edema: combined IVTA and laser treatment for PDR with CSMO. Int Ophthalmol 2005; 26: 207-214.
46. Lida T. Combined triamcinolone acetonide injection and grid laser photocoagulation: a promising treatment for diffuse diabetic macular edema? Br J Ophthalmol 2007; 91: 407-408.
47. Shimura M, Nakazawa T, Yasuda K, Shiono T, Nishida K. Pretreatment of posterior subtenon of triamcinolone acetonide has beneficial effects for gird pattern photocoagulation against diffuse diabetic macular oedema. Br J Ophthalmol 2007; 91: 449-454.
48. Kang SW, Sa HS, Cho HY, Kim JL. Macular gird photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006; 124: 653-658.
49. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
50. Cabrera López F, Cabrera Marrero B, Baeta Bayón L, Jerez Olivera E, Cardona Guerra P. Actualización en el diagnóstico y tratamiento del edema macular diabético. Arch Soc Can Oftalmol 2005; 16: 69-82.
51. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992; 99: 753-759.
52. Harbour JW, Smiddy WE, Flynn HW Jr, Rubsamen PE. Vitrectomy for diabetic macular edema associated with thickened and taut posterior hyaloid membrane. Am J Ophthalmol 1996; 121: 405-413.
53. Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of than posterior hyaliod and the inner limiting membrane. Retina 2000; 20: 126-133.
54. Avic R, Karderli B, Avic B, Simsek S, Baykara M, Kahveci Z, et al. Pars plana vitrectomy and removal of the internal limiting membrane in the treatment of chronic macular edema. Graefes Arch Clin Exp Ophthalmol 2004; 242: 845-852.
55. Recchia FM, Ruby AJ, Recchia CA. Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema. Am J Ophthalmol 2005; 139: 447-454.
56. Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, et al. Vitrectomy for diffuse diabetic macular edema associated with taut premacular posterior hyaloid. Am J Ophthalmol 2000; 130: 178-186.
57. Lövestam-Adran M, Larsson J. Vitrectomy seems to be beneficial for advanced diffuse diabetic macular oedema not responding to laser treatment. Int Ophthalmol 2005; 26: 21-26.
58. Matsumoto H, Yamanaka I, Hisatomi T, Enaida H, Ueno A, Hata Y, et al. Triamcinolone assisted pars plana vitrectomy improves residual posterior vitreus hyaloid removal: ultrastructural analysis of the inner limiting membrane. Retina 2007; 27:174-179.
59. Bahadir M, Ertan A, Mertoglu O. Visual acuity comparision of vitrectomy with and without internal limitig membrane removal in the treatment of diabetic macular edema. Int Ophthalmol 2005; 26: 3-8.
60. Patel JI, Hykin PG, Schadt M, Luong V, Fitzke F, Gregor ZJ. Pars plana vitrctomy with and without peeling of the inner limiting membrane for diabetic macular edema. Retina 2006; 26: 5-13.
61. Aboutable T. Is removal of internal limiting membrane always necessary during surgery for refractory diffuse diabetic macular edema without evident epimacular proliferation? Klin Mmonatsbl Augenheilkd 2006; 223: 681-686.
62. Meyer CH. Current treatment approaches in diabetic macular edema. Opthalmologica 2007; 221: 118-131.
63. Browning DJ, Fraser CM, Powers ME. Comparison of the magnitude and time course of macular thinning induced by different interventions for diabetic macular edema: implications for sequence of application. Ophthalmology 2006; 113: 1713-1719.
64. Yanyali A, Nohutcu AF, Horozoglu F, Celik E. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol 2005; 139: 795-801.
65. Jonas JB. Intravitreal triamcinolone acetonide: a change in paradigm. Ophthalmic Res 2006; 38: 218-245.
66. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kampeter BA. Intraocular pressure elevation after triamcinolone acetonide injection. Ophthalmology 2006; 112: 593-598.
67. Kreissig I, Degenring RF, Jonas JB. Diffuse diabetic macular edema. Intraocular pressure after intravitreal triamcinolone acetonide. Ophthalmologe 2005; 102: 153- 157.
68. Jonas, Kreissig I, Budde WM, Degenring RF. Cataract surgery combined with intravitreal triamcinolone acetonide. Eur J Ophthalmol 2005; 15: 329-335.
69. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 2005; 25: 556-560.
70. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand 2005; 83: 645-663.
71. Spandau UH, Derse M, Schmiz-Valckemberg P, Papoulis C, Jonas JB. Dosage dependency of intravitreal triamcinolone acetonide as treatment of diabetic macular oedema. Br J Ophthalmol 2005; 89: 999-1003.
72. Gibran SK, Cullinae A, Jungkim S, Cleary PE. Intravitreal triamcinolone for diffuse diabetic macular edema. Eye 2000; 20: 720-724.
73. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun J. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004; 138: 158-160.
74. A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema. Clinical Trial Gov Identifier: NCT00148265.
75. Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema. Clinical Trial Gov Identifier: NCT00309192.
76. Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema (LRT for DME). Clinical Trial Gov Identifier: NCT00444600.
77. Tachi N, Ogino N. Vitrectomy for diffuse diabetic macular edema in cases of diabetic retinopathy. Am J Ophthalmol 1996; 122: 258-260.
78. Otani T, Kishi S. A cotrolled study of vitrectomy for diabetic macular edema. Am J Ophthalmol 2002; 134: 214- 219.
79. Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina 2008; 28: 420- 426.
80. Hartley KL, Smiddy WE, Flynn HW Jr, Murray TG. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina 2008; 28:410-419.
81. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140: 695-698.
82. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-1449.
83. Ho TC, Lai WW, Lam DS. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2006; 141: 786-787.
84. Chung EJ, Roh MI, Kwon OW, Koh HJ . Effects of macular ischemia on the outcome of intravitreal Bevacizumab therapy for diabetic macular edema. Retina 2008; 28: 957-963.